{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:28:31Z","timestamp":1791883711692,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.medmal.2020.01.001","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T07:59:25Z","timestamp":1580889565000},"page":"316-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Comparative review of imipenem\/cilastatin versus meropenem"],"prefix":"10.1016","volume":"50","author":[{"given":"A.","family":"Salmon-Rousseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Blot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chavanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Piroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2020.01.001_bib0350","series-title":"Pr\u00e9cis de pharmacologie: du fondamental \u00e0 la clinique. \u00e9d. Les presses de l\u2019universit\u00e9 de Montr\u00e9al","author":"Beaulieu","year":"2015"},{"key":"10.1016\/j.medmal.2020.01.001_bib0355","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2020.01.001_bib0360","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.bcp.2005.12.003","article-title":"Redefining penems","volume":"71","author":"Dalhoff","year":"2006","journal-title":"Bioch Pharmacol"},{"key":"10.1016\/j.medmal.2020.01.001_bib0365","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/AAC.01529-07","article-title":"Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia Coli and Pseudomonas aeruginosa","volume":"52","author":"Davies","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"10.1016\/j.medmal.2020.01.001_bib0370","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jac\/24.suppl_A.125","article-title":"Antibacterial activity of meropenem against Gram-negative bacteria with a permeability defect against staphylococci","volume":"24","author":"Kitzis","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0375","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/S1624-0693(09)75318-6","article-title":"Comparative review of carbapenems","volume":"18","author":"Wolff","year":"2009","journal-title":"R\u00e9animation"},{"key":"10.1016\/j.medmal.2020.01.001_bib0380","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.amjmed.2006.03.013","article-title":"Resistance in Gram-negative bacteria: entero- bacteriaceae","volume":"119","author":"Paterson","year":"2006","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.medmal.2020.01.001_bib0385","first-page":"215","article-title":"Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects","volume":"9","author":"Zhanel","year":"1998","journal-title":"Can J Infect Dis"},{"key":"10.1016\/j.medmal.2020.01.001_bib0390","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1128\/AAC.00910-07","article-title":"Comparative antianaerobic activities of doripenem determined by mic and time-kill analysis","volume":"52","author":"Credito","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0395","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jac\/dkh298","article-title":"Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bacterici- dal action and preliminary in vitro methods evaluations","volume":"54","author":"Jones","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0400","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clinthera.2009.01.013","article-title":"Doripenem monohydrate, a broad-spectrum carbapenem antibiotic","volume":"31","author":"Matthews","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.medmal.2020.01.001_bib0405","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.42.1.94","article-title":"In vitro and in vivo antibacterial activities of S-4661, a new carbapenem","volume":"42","author":"Tsuji","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0410","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/AAC.45.6.1860-1867.2001","article-title":"In vitro activities of ertapenem (Mk-0826) against recent clinical bacteria collected in Europe and Australia","volume":"45","author":"Livermore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0415","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1469-0691.2005.01271.x","article-title":"Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)","volume":"11","author":"Fritsche","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medmal.2020.01.001_bib0420","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1128\/AAC.48.4.1384-1396.2004","article-title":"In vitro antimicrobial activity of doripenem, a new carbapenem","volume":"48","author":"Ge","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0425","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1179\/joc.2002.14.3.227","article-title":"Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections","volume":"14","author":"Pelak","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0430","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.diagmicrobio.2009.01.022","article-title":"Activity of a novel carbapenem, doripenem, against anaerobic pathogens","volume":"63","author":"Goldstein","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2020.01.001_bib0435","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/00003495-200059030-00016","article-title":"A review of its use in patients in intensive care units","volume":"59","author":"Hurst","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2020.01.001_bib0440","series-title":"The use of antibiotics","first-page":"227","author":"Kucers","year":"1997"},{"issue":"4","key":"10.1016\/j.medmal.2020.01.001_bib0445","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00003088-200039040-00003","article-title":"Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy","volume":"39","author":"Thalhammer","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.medmal.2020.01.001_bib0450","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13054-015-0818-8","article-title":"A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics","volume":"19","author":"Roberts","year":"2015","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.medmal.2020.01.001_bib0455","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jcph.601","article-title":"Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations","volume":"56","author":"Nehus Ej","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.medmal.2020.01.001_bib0460","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijantimicag.2014.09.009","article-title":"Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent\u00a0bolus administration","volume":"45","author":"Jamal","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.medmal.2020.01.001_bib0465","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1128\/AAC.00712-15","article-title":"Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements","volume":"59","author":"Ulldemolins","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.medmal.2020.01.001_bib0470","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1469-0691.2007.01868.x","article-title":"Parenteral carbapenems","volume":"14","author":"Shah","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medmal.2020.01.001_bib0475","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.TA.0000056164.26493.28","article-title":"Imipenem levels are not predictable in the critically-ill patient","volume":"56","author":"Belzberg","year":"2004","journal-title":"J Trauma"},{"issue":"5","key":"10.1016\/j.medmal.2020.01.001_bib0480","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/jac\/dkx526","article-title":"Development of a dosing nomogram for continuous infusion meropenem in critically ill patients based on a validated population pharmacokinetic model","volume":"73","author":"Minichmayr\u00a0IK","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0485","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1128\/AAC.01318-06","article-title":"Population pharmacokinetics and pharmaco-dynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized controlled trial","volume":"51","author":"Sakka","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.medmal.2020.01.001_bib0490","first-page":"2803","article-title":"Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions","volume":"43","author":"Bigley","year":"1986","journal-title":"AJHP"},{"key":"10.1016\/j.medmal.2020.01.001_bib0495","first-page":"156","article-title":"Stability of meropenem in saline and dextrose solution and compatibility with potassium chloride","volume":"51","author":"Walker","year":"1998","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.medmal.2020.01.001_bib0500","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ajhp\/61.16.1682","article-title":"Stability of meropenem in polyvinyl chloride bags and elastomeric infusion device","volume":"61","author":"Smith","year":"2004","journal-title":"Am J health-Syst Pharm"},{"key":"10.1016\/j.medmal.2020.01.001_bib0505","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ajhp\/54.4.412","article-title":"Stability of meropenem in intravenous solutions","volume":"54","author":"Patel","year":"1997","journal-title":"Am J health-Syst Pharm"},{"issue":"1","key":"10.1016\/j.medmal.2020.01.001_bib0510","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1517\/14656566.9.1.23","article-title":"Carbapenems: a potent class off antibiotics","volume":"9","author":"Nicolau David","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0515","first-page":"168","article-title":"Stability of meropenem in elastomeric portable infusion devices","volume":"3","author":"Kr\u00e4mer","year":"1997","journal-title":"Eur Hosp Pharm"},{"issue":"5","key":"10.1016\/j.medmal.2020.01.001_bib0520","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/jop.1999.15.439","article-title":"Penetration and decay of meropenem into the human aqueous humor and vitreous","volume":"15","author":"Schauersberger","year":"1999","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.medmal.2020.01.001_bib0525","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/112067219400400207","article-title":"Human vitreous penetration of imipenem","volume":"4","author":"Adenis","year":"1994","journal-title":"Eur J Ophthalmol"},{"issue":"12","key":"10.1016\/j.medmal.2020.01.001_bib0530","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1128\/AAC.00497-11","article-title":"Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment","volume":"55","author":"Ikawa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.medmal.2020.01.001_bib0535","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijantimicag.2012.11.001","article-title":"Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic\/pharmacodynamic evaluation","volume":"41","author":"Nishikawa","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.medmal.2020.01.001_bib0540","first-page":"503","article-title":"Diffusion of imipenem in synovial fluid","volume":"39","author":"P\u00e9chinot","year":"1991","journal-title":"Pathol Biol (Paris)"},{"issue":"Suppl. E","key":"10.1016\/j.medmal.2020.01.001_bib0545","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/18.Supplement_E.93","article-title":"The pharmacokinetics and tissue penetration of imipenem","volume":"18","author":"Wise","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0550","first-page":"475","article-title":"Antibiotics bioavailability in acute experimental pancreatitis","volume":"178","author":"Trudel","year":"1994","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.medmal.2020.01.001_bib0555","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/jac\/20.5.725","article-title":"Imipenem kinetics in serum, lung tissue and pericardial fluid in patients undergoing thoracotomy","volume":"20","author":"Benoni","year":"1987","journal-title":"J Antimicrob Chemother"},{"issue":"2 Suppl.","key":"10.1016\/j.medmal.2020.01.001_bib0560","first-page":"259","article-title":"Penetration of imipenem-cilastatin into the lung tissue and pericardial fluid of thoracotomized patients","volume":"6","author":"Benoni","year":"1987","journal-title":"Chemioterapia"},{"key":"10.1016\/j.medmal.2020.01.001_bib0565","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jac\/28.6.911","article-title":"Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion","volume":"28","author":"Mouton","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0570","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1128\/AAC.43.3.681","article-title":"Penetration of meropenem in lung, bronchial mucosa, and pleural tissues","volume":"43","author":"Byl","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.medmal.2020.01.001_bib0575","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1093\/clinids\/24.Supplement_2.S178","article-title":"Tissue penetration of meropenem in patients under-going gynecologic surgery","volume":"24","author":"Gall","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2020.01.001_bib0580","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1179\/joc.2008.20.5.615","article-title":"The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients","volume":"20","author":"Tsumura","year":"2008","journal-title":"J Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0585","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1128\/AAC.42.8.2012","article-title":"Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy","volume":"42","author":"Nau","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0590","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.wneu.2016.11.040","article-title":"Evaluation of Meropenem Penetration into Cerebrospinal Fluid in Patients with Meningitis After Neurosurgery","volume":"98","author":"Zhang","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.medmal.2020.01.001_bib0595","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1592\/phco.27.9.1334","article-title":"Safe use of meropenem in a patient with a possible non-immediate allergy to imipenem","volume":"27","author":"Lakhal","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medmal.2020.01.001_bib0600","series-title":"Doripenem: a carbapenem with low seizure-inducing potential [abstract]. Presented at the 48th annualICAAC\/IDSA 46th annual meeting: a joint meeting of the American Society for Microbiology and the Infectious Diseases Society of America","author":"Zhanel","year":"2008"},{"issue":"5","key":"10.1016\/j.medmal.2020.01.001_bib0605","doi-asserted-by":"crossref","first-page":"408","DOI":"10.7164\/antibiotics.48.408","article-title":"Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain","volume":"48","author":"Sunagawa","year":"1995","journal-title":"J Antibiot (Tokyo)"},{"issue":"suppl A","key":"10.1016\/j.medmal.2020.01.001_bib0610","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/36.suppl_A.207","article-title":"Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem","volume":"36","author":"Norrby","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0615","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2047-2994-1-39","article-title":"The gut is the epicentre of antibiotic resistance","volume":"1","author":"Carlet","year":"2012","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.medmal.2020.01.001_bib0620","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1128\/AAC.47.11.3610-3612.2003","article-title":"Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum-\u03b2-lactamases","volume":"47","author":"Hoyen","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0625","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1128\/AAC.01823-12","article-title":"Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients","volume":"57","author":"Armand-Lefevre","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.medmal.2020.01.001_bib0630","doi-asserted-by":"crossref","first-page":"S432","DOI":"10.1093\/clinids\/7.Supplement_3.S432","article-title":"Effect of imipenem\/cilastatin on the colonic microflora","volume":"7","author":"Nord","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.medmal.2020.01.001_bib0635","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/AAC.33.2.204","article-title":"Imipenem concentrations in colorectal surgery and impact on the colonic microflora","volume":"33","author":"Kager","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2020.01.001_bib0640","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-9343(85)90100-7","article-title":"Impact of imipenem\/cilastatin therapy on normal fecal flora","volume":"78","author":"Wexler","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.medmal.2020.01.001_bib0645","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/00365549309008529","article-title":"Effects of imipenem, cefotaxime and cotrimoxazole on aerobic microbial colonization of the digestive tract","volume":"25","author":"Van der Leur","year":"1993","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"10.1016\/j.medmal.2020.01.001_bib0650","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijantimicag.2017.02.018","article-title":"Unexpected persistence of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in the faecal microbiota of hospitalised patients treated with imipenem","volume":"50","author":"Grall","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.medmal.2020.01.001_bib0655","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/BF01963943","article-title":"Effect of meropenem on the intestinal microflora","volume":"10","author":"Bergan","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2020.01.001_bib0660","unstructured":"Anonyme. Le Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes. https:\/\/www.lecrat.fr\/articleSearchSaisie.php?recherche=meropenem and https:\/\/www.lecrat.fr\/articleSearch.php?id_grou*pe=12.(accessed on December 1,2018)."},{"issue":"12","key":"10.1016\/j.medmal.2020.01.001_bib0665","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/AAC.36.12.2652","article-title":"Pharmacokinetics and transplacental passage of imipenem during pregnancy","volume":"36","author":"Heikkil\u00e4","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.medmal.2020.01.001_bib0670","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007691-200310000-00009","article-title":"Carbapenems in pediatrics","volume":"25","author":"Ayalew","year":"2003","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.medmal.2020.01.001_bib0675","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","article-title":"Meropenem: a review of its use in the treatment of serious bacterial infections","volume":"68","author":"Baldwin","year":"2008","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.medmal.2020.01.001_bib0680","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.medmal.2020.01.001_bib0685","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/19490976.2016.1218584","article-title":"Antibiotic perturbation of the preterm infant gut microbiome and resistome","volume":"7","author":"Gasparrini","year":"2016","journal-title":"Gut Microbes"},{"key":"10.1016\/j.medmal.2020.01.001_bib0690","doi-asserted-by":"crossref","first-page":"16024","DOI":"10.1038\/nmicrobiol.2016.24","article-title":"Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome","volume":"1","author":"Gibson","year":"2016","journal-title":"Nat Microbiol"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X20300251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X20300251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:18:06Z","timestamp":1759972686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X20300251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0399077X20300251"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2020.01.001","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative review of imipenem\/cilastatin versus meropenem","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2020.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}